Pipeline

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
Program Cell Type
Functionality
Target(s) Indication(s) Research PreClin Phase 1 Phase 2 Phase 3
iPSC-derived Cell Products
FT516 iNK
hnCD16
CD20 BCL + CD20 mAb

 Hematology

n/a AML

 

FT596 iNK
hnCD16 + IL15RF + CAR-19
CD19, CD20 BCL, CLL ± CD20 mAb

 

FT538 iNK
hnCD16 + IL15RF + CD38-KO
n/a AML

CD38 MM + CD38 mAb

 

EGFR/HER2/PD1/PD-L1 Solid Tumors + mAb

 Solid Tumor

FT576 iNK
hnCD16 + IL15RF + CD38-KO + CAR-BCMA
BCMA, CD38 MM ± CD38 mAb

 

FT819 iT
CAR-19, TCR-KO
CD19 Hematology

 

FT536 iNK
hnCD16 + IL15RF + CD38-KO + CAR-MICA/B
MICA/B Solid tumors ± mAb

 

FT873 iT
hnCD16 + IL7RF + CAR-B7H3
B7H3 Solid tumors ± mAb

 

iPSC-derived Cell Products – Cancer Immunotherapy Collaborations
FT555/
Janssen
iNK
hnCD16 + IL15RF + CD38-KO + CAR-GPRC5D
GPRC5D, CD38 MM ± CD38 mAb

 

Janssen iNK,iT KLK2; undisclosed 3 tumor targets

 

FT825/Ono iNK,iT HER2; undisclosed 2 tumor targets

 

iPSC-DERIVED CELL PRODUCTS

Program Indication Phase
FT500
iNK
Non-engineered
Solid tumors + CPI 1
FT516
iNKhnCD16
AML 1
BCL + CD20 mAb 1
Solid tumors + PD-L1 mAb 1
FT596
iNK
hnCD16 + IL15RF + CAR-19
BCL, CLL ± CD20 mAb 1
FT538
iNK
hnCD16 + IL15RF + CD38-KO
AML 1
MM + CD38 mAb 1
Solid Tumors + mAb 1
FT576
iNK
hnCD16 + IL15RF + CD38-KO + CAR-BCMA
MM ± CD38 mAb 1
FT819
iT
CAR-19, TCR-KO
Hematology 1
FT536
iNK,iT
hnCD16 + IL15RF + CD38-KO + CAR-MICA/B
Solid tumors ± mAb 1
FT873
iNK,iT
hnCD16 + IL7RF + CAR-B7H3
Solid tumors ± mAb Pre

iPSC-DERIVED CELL PRODUCTS – CANCER IMMUNOTHERAPY COLLABORATIONS

Program Indication Phase
FT555/Janssen
iNK
hnCD16 + IL15RF + CD38-KO + CAR-GPRC5D
MM ± CD38 mAb Preclinical
Janssen
iNK/iT
3 tumor targets Preclinical
Ono Pharma
iNK/iT
2 tumor targets Preclinical

iPSC = induced pluripotent stem cell iNK = iPSC-derived NK Cell iT = iPSC-derived T cell mAb = monoclonal antibody CPI = checkpoint inhibitor hnCD16 = high affinity, non-cleavable CD16 Fc receptor IL15-RF = IL15 receptor fusion CD38-KO = CD38 knock-out CAR = chimeric antigen receptor TCR-KO = T-cell receptor knock-out AML = acute myelogenous leukemia BCL = B-cell lymphoma CLL = chronic lymphocytic leukemia  MM = Multiple myeloma